business
Fate Therapeutics To Present Off-The-Shelf CAR T Portfolio At ACR Convergence 2026
Fate Therapeutics (FATE) announced four abstracts selected for ACR Convergence 2026, highlighting its off-the-shelf, iPSC-derived CAR T-cell portfolio for autoimmune diseases.
Read full article on Rttnews